ADMA Biologics Issues Detailed Rebuttal to Short-Seller Allegations with Supporting Data

summarizeSummary

ADMA Biologics filed an 8-K to formally respond to a short-seller report, providing detailed data and explanations to refute allegations regarding product demand, inventory levels, competitive positioning, and financial practices.

check_boxKey Events

• Short-Seller Allegations Refuted

  ADMA Biologics issued a detailed statement refuting claims made by Culper Research regarding its business practices and operations, following a short-seller report issued on March 24, 2026.

• Product Demand and Inventory Data Provided

  The company provided data from distribution partners and direct customers demonstrating growing end-user demand for ASCENIV and BIVIGAM. It clarified that distributor inventory levels are consistent with industry standards, with ASCENIV showing 48 days and BIVIGAM 51 days of coverage above safety stock as of March 22, 2026, refuting channel stuffing allegations.

• Competitive Positioning Clarified

  ADMA explained that ASCENIV is positioned as a late-line therapy for immune-compromised individuals, commanding premium pricing, and is not directly impacted by new normal immune globulin product launches.

• Financial and Governance Affirmations

  ADMA confirmed receiving unqualified audit opinions for FY2024 and FY2025 from a Big Four accounting firm and explicitly denied any undisclosed related party transactions involving the Grossman family.

auto_awesomeAnalysis

This 8-K is a critical response to a short-seller report, providing detailed, data-backed refutations to allegations concerning product demand, channel stuffing, competitive positioning, audit integrity, and related-party transactions. The company's proactive disclosure of specific inventory and demand data aims to alleviate market confusion and restore investor confidence following the negative report. This comprehensive rebuttal is important for clarifying the company's operational health and financial transparency.